Halozyme Therapeutics, Inc.

DB:RV7 Stock Report

Market Cap: €6.0b

Halozyme Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Halozyme Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

3.6%

Buyback Yield

Total Shareholder Yield3.6%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

Recent updates

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if RV7's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RV7's dividend payments have been increasing.


Dividend Yield vs Market

Halozyme Therapeutics Dividend Yield vs Market
How does RV7 dividend yield compare to the market?
SegmentDividend Yield
Company (RV7)n/a
Market Bottom 25% (DE)1.7%
Market Top 25% (DE)4.9%
Industry Average (Biotechs)1.6%
Analyst forecast (RV7) (up to 3 years)n/a

Notable Dividend: Unable to evaluate RV7's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RV7's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate RV7's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RV7 has not reported any payouts.


Discover strong dividend paying companies